Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Corporate Authors:
      VALIANT Investigators
    • المصدر:
      Publisher: Wiley Country of Publication: England NLM ID: 100887595 Publication Model: Print Cited Medium: Print ISSN: 1388-9842 (Print) Linking ISSN: 13889842 NLM ISO Abbreviation: Eur J Heart Fail Subsets: MEDLINE
    • بيانات النشر:
      Publication: 2014- : Chichester : Wiley
      Original Publication: Amsterdam ; New York : Elsevier Science, c1999-
    • الموضوع:
      Angiotensin Receptor Antagonists*; Heart Failure/*drug therapy ; Myocardial Infarction/*drug therapy ; Tetrazoles/*therapeutic use ; Valine/*therapeutic use; Aged ; Captopril/therapeutic use ; Double-Blind Method ; Female ; Glyceraldehyde-3-Phosphate Dehydrogenases/therapeutic use ; Heart Failure/physiopathology ; Humans ; Male ; Middle Aged ; Multicenter Studies as Topic ; Peptide Fragments/therapeutic use ; Randomized Controlled Trials as Topic ; Valine/analogs & derivatives ; Valsartan ; Ventricular Dysfunction, Left/drug therapy
    • نبذة مختصرة :
      Background: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial compared outcomes with: (1) angiotensin-converting enzyme inhibition (ACEI) with the reference agent captopril; (2) angiotensin-receptor blockade (ARB) with valsartan; or (3) both in patients with heart failure (HF) and/or left ventricular systolic dysfunction (LVSD) after myocardial infarction (MI).
      Aims: a goal of this active-control trial was to simulate conditions that would lead current practitioners to use ACEIs. Thus, we compared characteristics of VALIANT patients with those of patients in placebo-controlled trials that established ACEIs as standard treatment.
      Methods and Results: We collected demographic, clinical, medication and imaging information from 14703 patients in 24 countries. This high-risk population was a median 65.8 years old, and 31.1% were female. Most (51.8%) showed imaging evidence of LVSD at enrollment. Most (72%) had Killip class>/=II HF. Patients received evidence-based therapies at rates similar to those of contemporary MI trials and at an improved rate compared with prior placebo-controlled ACEI trials.
      Conclusion: VALIANT represents the largest globally representative cohort enrolled with HF and/or LVSD after MI. Patients were similar to those in placebo-controlled ACEI trials while reflecting improvements in evidence-based care. With enrollment complete, VALIANT is poised to define the optimal strategy for renin-angiotensin system blockade after MI to improve cardiovascular outcomes.
    • الرقم المعرف:
      0 (Angiotensin Receptor Antagonists)
      0 (Peptide Fragments)
      0 (Tetrazoles)
      130349-12-1 (glyceraldehyde 3-phosphate dehydrogenase (304-313))
      80M03YXJ7I (Valsartan)
      9G64RSX1XD (Captopril)
      EC 1.2.1.- (Glyceraldehyde-3-Phosphate Dehydrogenases)
      HG18B9YRS7 (Valine)
    • الموضوع:
      Date Created: 20030819 Date Completed: 20031223 Latest Revision: 20190513
    • الموضوع:
      20221213
    • الرقم المعرف:
      10.1016/s1388-9842(03)00112-0
    • الرقم المعرف:
      12921816